Abstracts tagged "Patient reported outcomes"

Abstract Number: 1586 • ACR Convergence 2020
Rheum Service: Comprehensive Virtual Care During COVID-19
Stephanie Gottheil¹ and Joseph Carson¹, ¹London Rheumatology, London, ON, Canada
Background/Purpose: During COVID-19, patients require timely access to rheumatologists while adhering to physical distancing guidelines. In this quality improvement project, we developed a comprehensive virtual…
Abstract Number: 1734 • ACR Convergence 2020
The Challenge of Assessing Wellbeing from the Patients` Perspective in Early Rheumatoid Arthritis
Diederik De Cock¹, Tianna Poffe², Geert Verbeke², Sofia Pazmino¹, Veerle Stouten¹, Delphine Bertrand¹, Rene Westhovens³ and Patrick Verschueren⁴, ¹KU Leuven, Leuven, Belgium, ²KU Leuven, Leuven, ³University Hospitals Leuven, Belgium, Leuven, Belgium, ⁴University Hospital Leuven, Leuven, Belgium
Background/Purpose: Although more effective therapeutics and treatment strategies for Rheumatoid Arthritis (RA) have improved many patient-reported outcomes (PROs), still a sizeable number of patients in…
Abstract Number: 0141 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from FINCH-1 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, Hao Hu³, Thijs Hendrikx⁴, Annelies Boonen⁵, David Walker⁶, Rieke Alten⁷ and Bernard Combe⁸, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Maastricht University Medical Center, Maastricht, Netherlands, ⁶Northumbria Healthcare Trust, North Shields, United Kingdom, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ⁸University of Montpellier, Montpellier, France
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…
Abstract Number: 0162 • ACR Convergence 2020
Identifying Sleep Problems in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients with Patient-reported Outcomes (PRO) Questionnaires
Kim Nguyen¹, Christopher Towe², Shima Yasin³, Alexei Grom⁴, Hermine I Brunner⁵ and Grant Schulert⁵, ¹Veterans Affairs Cincinnati, University of Cincinnati Medical Center, Cincinnati, ²Cincinnati Children's Medical Hospital Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) can cause severe and chronic multisystem involvement. Medical therapies including high-dose corticosteroids can have significant side effects affecting sleep.…
Abstract Number: 0347 • ACR Convergence 2020
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Proton Rahman¹, Philip Helliwell², Atul Deodhar³, Alexa Kollmeier⁴, Elizabeth Hsia⁵, Bei Zhou⁶, Xiwu Lin⁶, Chenglong Han⁶ and Philip Mease⁷, ¹Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2 are phase-3 trials of guselkumab (GUS, an IL-23 inhibitor) in patients with psoriatic arthritis (PsA). In both trials, treatment with…
Abstract Number: 0814 • ACR Convergence 2020
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
Rishi Gupta¹, Muhammad Shipa², Su-Ann Yeoh², Pauline Buck¹ and Michael Ehrenstein², ¹University College London Hospital, London, United Kingdom, ²University College London, LONDON, United Kingdom
Background/Purpose: During the COVID-19 pandemic, rapid guidelines by the National Institute for Health and Care Excellence (NICE) in the United Kingdom[1] recommended consideration of switching…
Abstract Number: 1142 • ACR Convergence 2020
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Rebecca Overbury¹, Tracy Frech², John Bohnsack³, CJ Inman¹, Sara Stern¹, Karen James¹, Erin Treemarcki⁴ and Aimee Hersh⁴, ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ³University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁴University of Utah and Primary Children's Hospital, Salt Lake City
Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…
Abstract Number: 1288 • ACR Convergence 2020
Predictors of Frailty Identified by the Short Physical Performance Battery and Associations with Patient-reported Outcomes
Patricia Katz¹, Jinoos Yazdany², Laura Trupin³, Stephanie Rush², Cristina Lanata³, Lindsey Criswell⁴ and Maria Dall'Era⁵, ¹University of California, San Francisco, Novato, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Frailty, defined as a generalized vulnerability to stressors, has emerged as a relevant concept in SLE1, although its origins are in geriatrics. As defined…
Abstract Number: 1595 • ACR Convergence 2020
Using Rheumatoid Arthritis Communication Tool Developed by the RISE Learning Collaborative to Promote Shared Decision-Making
Joad Eseddi¹, Puneet Bajaj², Gabriela Schmajuk³, Jinoos Yazdany⁴ and Salahuddin Kazi⁵, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX, ³University of California, San Francisco, Atherton, CA, ⁴University of California, San Francisco, San Francisco, CA, ⁵Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Patient care is moving from physician directed treatment to a co-design framework that focuses on creating a partnership between patients and physicians. This new…
Abstract Number: 1738 • ACR Convergence 2020
Promote Treat-to-Target for RA via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Jing Yang¹, Rong Mu², Chun Li³, Bin Wu⁴, Hongzhi Wang⁵, Wenqiang Fan⁶, Jinmei Zou⁷, Yu Zhang¹, Fen Li⁸, Xiaofeng Rong⁹, Jianhong Wu¹⁰, Yong Wang¹¹, Shengguang Li¹², Yi Zhao¹³, Xiaoqiang Hou¹⁴, Hui Xiao¹⁵, Yuhua Jia¹⁶, Bing Wu¹⁶, Miaomiao Song¹⁶, Fei Xiao¹⁶ and Zhanguo Li¹⁷, ¹Department of Rheumatology, Mianyang Central Hospital, Mianyang, China (People's Republic), ²People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ³People's Hospital, Beijing University Medical School, beijing, China (People's Republic), ⁴Chongqing Hospital of Traditional Chinese Medicine, chongqing, China (People's Republic), ⁵The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁶Central Hospital of XinXiang, Xinxiang, China (People's Republic), ⁷Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China (People's Republic), ⁸The Second Xiangya Hospital of Central South University, hunan, China (People's Republic), ⁹The First Affiliated Hospital of Chongqing Medical University, chongqing, China (People's Republic), ¹⁰Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), ¹¹The first Hospital Affiliated to AMU (Southernwest Hospital), chongqing, China (People's Republic), ¹²Peking University International Hospital, Beijing, China (People's Republic), ¹³Xuanwu Hospital, Capital Medical University, Beijing, China, Beijing, China (People's Republic), ¹⁴Yichang Central People's Hospital, Beijing, China (People's Republic), ¹⁵Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁶Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁷Peking University People’s Hospital, Xicheng, Beijing, China (People's Republic)
Background/Purpose: Treat-to-Target (T2T) strategy are critical for the treatment of RA, but Chinese rheumatologists can hardly provide patients with a complete assessment in the clinic…
Abstract Number: 2692 • 2015 ACR/ARHP Annual Meeting
The Patients Evaluation of Pain and Disease Activity As Well As Improvement during One-Year Follow-up on Etanercept Treatment Is Highly Associated to Subjective Factors and Not to Objective Assessments Including Ultrasound
Hilde Berner Hammer¹ and Jon Lampa², ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Patient reported outcomes (PROs) are important for evaluation of treatment response in patients with rheumatoid arthritis (RA). Ultrasound (US) is a sensitive method for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].